Status:
COMPLETED
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma
Lead Sponsor:
AIDS Malignancy Consortium
Collaborating Sponsors:
National Cancer Institute (NCI)
The Emmes Company, LLC
Conditions:
Lymphoma
Eligibility:
All Genders
18-120 years
Phase:
PHASE2
Brief Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them o...
Detailed Description
OBJECTIVES: Primary * Determine the efficacy of rituximab, cyclophosphamide, vincristine, doxorubicin hydrochloride, and high-dose methotrexate (R-CODOX-M ) alone or alternating with rituximab and i...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed Burkitt's lymphoma (BL) or new WHO 2009 criteria B-cell lymphoma unclassified (with features intermediated between difuse large B-cell lymphoma and BL)
- Any stage disease
- Newly diagnosed disease
- Meets 1 of the following criteria for disease risk:
- Low-risk disease, defined by 1 of the following:
- Stage I with a single focus of disease \< 10 cm AND normal lactate dehydrogenase (LDH) level
- Totally resected intra-abdominal disease only AND normal LDH post surgery
- High-risk disease, defined as not meeting criteria for low-risk disease
- Measurable or nonmeasurable disease
- HIV-positive confirmed by enzyme-linked immunosorbent assay and Western blot OR by measurable HIV viral load
- No visceral Kaposi's sarcoma
- PATIENT CHARACTERISTICS:
- Karnofsky performance status 40-100%
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- LVEF ≥ 50% by MUGA or echocardiogram
- Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min
- Absolute neutrophil count ≥ 1,000/mm³
- Platelet count ≥ 50,000/mm³ (unless related to lymphoma)\*
- Direct bilirubin ≤ 2.0 mg/dL OR total bilirubin ≤ 3.5 mg/dL AND direct bilirubin normal (if elevated bilirubin secondary to antiretroviral therapy)
- AST and ALT ≤ 3 times upper limit of normal
- No other malignancy within the past 5 years except curatively treated cutaneous basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, or cutaneous Kaposi's sarcoma
- No other medical illness unrelated to non-Hodgkin's lymphoma, including any of the following:
- Uncontrolled infection (including opportunistic infection)
- Chronic renal insufficiency
- Myocardial infarction within the past 6 months
- Unstable angina
- Cardiac arrhythmias other than chronic atrial fibrillation
- Patients with active hepatitis B infection are eligible provided they receive concurrent dual antiviral therapy NOTE: \*Patients with bone marrow involvement are eligible irrespective of blood count
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior therapy for this disease except for 1 of the following :
- Seven consecutive days of steroids alone or in combination with a non-CHOP regimen necessary for patient stabilization (e.g., cyclophosphamide and steroids steroids for normalization of disease-related hyperbilirubinemia)
- One course of CHOP or fractionated CHOP (e.g. CODOX) with or without rituximab
- No epoetin alfa or filgrastim (G-CSF) within 24 hours of study chemotherapy
- No concurrent zidovudine
Exclusion
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT00392834
Start Date
September 1 2006
End Date
July 1 2013
Last Update
June 6 2018
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Rebecca and John Moores UCSD Cancer Center
La Jolla, California, United States, 92093-0658
2
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, United States, 90089-9181
3
UCLA Clinical AIDS Research and Education (CARE) Center
Los Angeles, California, United States, 90095-1793
4
UCSF Medical Center at Parnassus
San Francisco, California, United States, 94143-0296